Bloomberg News Now is a comprehensive audio report on today's top stories. Listen for the latest news, whenever you want it, covering global business stories around the world.

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Snopes tried to discredit research as a "rumor" when journalist received early results from conference call between researchers and study participants. Spike still detectable in some participants ...

The Make America Healthy Again commission is taking action on mRNA vaccines as several states consider legislation to ban ...

In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going to take a look at where Moderna, Inc.

UBS lowered the firm’s price target on Moderna (MRNA) to $78 from $96 and keeps a Buy rating on the shares. UBS believes Moderna’s oncology ...

The FDA is mired in uncertainty with some staffers losing their jobs over the weekend and more potentially to come, vaccines ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 179,268 call options on the company. This represents an increase ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...